Premature ovarian insufficiency
- 10 Dec 2023
- 1 Minute to read
- Print
- PDF
Premature ovarian insufficiency
- Updated on 10 Dec 2023
- 1 Minute to read
- Print
- PDF
Article summary
Did you find this summary helpful?
Thank you for your feedback
- Premature ovarian insufficiency (POI) is defined as loss of ovarian activity in women <40 years.
- The cut-off age of 40 years is used because this is >2 standard deviations below the average age of menopause.
- It is characterised by menstrual disturbance (amenorrhea or oligomenorrhea) with raised FSH levels.
- Those women with oligomenorrhea may have sporadic ovarian activity and have a small chance of spontaneous pregnancy (5-10%).
- There are many causes of POI, however, the majority of cases are idiopathic.
- It is estimated to affect around 1% of women <40 years, 0.1% <30 years and 0.01% <20 years.
- As cure rates of cancers in young women improve, it is likely that the incidence of iatrogenic POI will rise.
- POI can increase the risk of adverse health sequelae including cardiovascular disease, osteoporosis and cognitive impairment due to the low oestrogen status.
- Other names often used for POI include primary ovarian insufficiency, premature ovarian failure, premature menopause, gonadal dysgenesis and hypergonadotropic hypogonadism.
Note:
- NICE says: consider referring people with POI to healthcare professionals with the relevant experience to help them manage all aspects of physical and psychosocial health related to their condition.
- For information on the assessment and investigation of bleeding in the menopause transition see assessment section.
References and Further Information
- ESHRE guideline. Management of women with premature ovarian insufficiency. Human Reproduction. 2016.
- Daisy Network - patient support charity
- Menopause Practice Standards produced by the British Menopause Society (BMS), Royal College of Obstetricans and Gynaecologists (RCOG), Society for Endocrinology (SfE), Faculty of Sexual and Reproductive Health (FSRH), Faculty of Pharmaceutical Medicine (FPM) and Royal Pharmaceutical Society (RPS) 2022.
- Hamoda H, Panay N, Pedder H et al. The British Menopause Society & Women’s Health Concern 2020 recommendations on hormone replacement therapy in menopausal women. Found on page 195. Post Reprod Health 2020
- Hillard H, Abernethy K, Hamoda H et al. BMS handbook. Management of the menopause sixth edition. 2017. Page 130-1.
- NICE Menopause: diagnosis and management. NICE guideline 2015. Last updated 2019. Section 1.6.9.
- NICE CKS guidance. Management. When should I refer a woman with menopausal symptoms? Last revised Sept 2022.
- National Institute for Health and Clinical Excellence Guideline. Menopause update. Draft for Consultation. November 2023. Page 37
:::
Was this article helpful?